Vanderbilt researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.

Chic Awearness, a fundraiser for ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC), is an online event this year from now throughout September with an in-store shopping opportunity to close out the month called Chic Week.

Vanderbilt researchers used single-cell technologies to explore the accumulation of mutations during blood cancer progression, which could help identify strategies for preventing leukemia before it occurs.

Shane Jacobson, chief executive officer of the V Foundation for Cancer Research, on left, visited Vanderbilt-Ingram Cancer Center on Monday to meet with former and current recipients of funding from the foundation.

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer.

The circulating DNA that tumors release is a reliable metric of tumor genomics and can be used to monitor molecular changes in metastatic breast cancer.